Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Summit Therapeutics to kick off gonorrhoeae trial next year

Identified using the company’s Discuva Platform, the new drug is designed to exploit the N. gonorrhoeae target
Summit Therapeutics to kick off gonorrhoeae trial next year
Cases of the sexually transmitted disease are on the rise

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) said it will kick off a Phase I clinical trial of a new antibiotic for gonorrhoea in the second half of next year.

It follows the nomination of SMT-571 as its lead candidate to tackle the sexually transmitted infection.

READ: Summit Therapeutics awarded additional US$12mln under contract with US BARDA

Identified using the company’s Discuva Platform, it is designed to exploit the N. gonorrhoeae target.

The study itself will be supported by the US$4.5mln it received from CARB-X, a US programme designed to accelerate the development of new antibiotics.

The need for new treatments for gonorrhoea was laid bare last week when the Centers for Disease Control and Prevention showed that cases of the STI had increased by 67% between 2013 and 2017.

Worrying also was the rise in drug-resistant strains of the infection.

“We believe our new science and new way of thinking together enable our goal to develop the right drug for the right pathogen and create opportunities for success,” said Dr David Roblin, Summit’s head of R&D of Summit.

“SMT-571 is being developed specifically for gonorrhoea, meaning that it is designed to have both a targeted spectrum of activity and be tailored to meet the needs of patients with gonorrhoea.”

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
consumer health segment overview
The company sells clinically validated anti-ageing products for hair, skin and body.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use